Proprietary Technology

Antibody-Drug Conjugates (ADCs) consist of an antibody that is chemically linked to a cytotoxic payload to deliver potent cytotoxic agents directly to cancer cells. The antibody carries the payload to a cancer cell, where it is internalized and then released.

ADCs are rapidly gaining clinical and commercial momentum, with 11 ADCs already approved by the FDA and >100 ADCs in clinical trials.